智飞生物：HK.3-JN.1新型冠状病毒mRNA疫苗获得临床试验批准通知书

Core Viewpoint - The company, Zhifei Biological, has received approval from the National Medical Products Administration for its subsidiary's mRNA vaccine, HK.3-JN.1, to conduct clinical trials for the prevention of COVID-19 related diseases [1] Group 1 - Zhifei Biological's subsidiary, Anhui Zhifei Longcom Biopharmaceutical Co., Ltd., is responsible for the development of the HK.3-JN.1 mRNA vaccine [1] - The approval notification number for the clinical trial is 2026LP00481 [1] - The clinical trial aims to evaluate the vaccine's effectiveness in preventing diseases caused by the novel coronavirus [1]